Study indicates age and gender are factors in ocular gene therapy outcomes

News
Article

Researchers from the University of Bristol recorded increased instances of inflammation in particular demographic groups

On the left, a close-up of a young woman's face. On the right, a close-up of an older woman's face. They both stare directly at the camera. Image credit: ©evafesenuk – stock.adobe.com

Inflammation lasted longer and was more severe in all older patient models, regardless of gender. Image credit: ©evafesenuk – stock.adobe.com

Findings from a new study via the University of Bristol indicate that age and gender may play a part in patient outcomes following ocular gene therapy. Lead author Alison Clare, PhD, BSc (hons), a senior research associate from Bristol Medical School: Translational Health Sciences (Ophthalmology), and her colleagues published the findings in Molecular Therapy. Their study focused on ocular gene therapy delivered by an adeno-associated virus (AAV) system. Patients may experience adverse effects if the immune system reacts to the delivery virus with inflammation. This can lead to decreased effectiveness of the gene therapy, either due to the inflammation itself or by creating limitations around dosing due to the adverse response.1

The University of Bristol research team used animal models to compare patient responses to AAV therapy, studying male and female eye cells across different age groups (young, middle-aged and older patients).2 Eyes of older females exhibited an increased incidence of inflammation or other reactions, which caused damage to the eye. Additionally, inflammation lasted longer and was more severe in all older patient models, regardless of gender. Older males exhibited a consistent immune response pattern, more severe than their younger male counterparts, while cells from older females had a stronger stress and inflammation response. These reactions in older female models were linked to signs of retinal cell damage. While immune cells, such as microglia and T cells, did exhibit different response characteristics among young female and young male animal models, the young animal models presented a “similar short-term immune response” regardless of gender.1

“Our findings are the first to demonstrate age and sex influences the risk of significant adverse inflammatory reactions in the eye to gene therapies. The research has highlighted the critical need to separate patients for gene therapy treatment based on gender, age and risk,” Dr Clare said in a statement.1 “It also underlines the need to understand the risk-reward benefit for gene therapy and indicates older female patients could be at risk from serious adverse effects by any prospective eye gene therapy.”

The research was supported by National Institute for Health and Care Research (NIHR) Biomedical Research Centre, based at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology; global charitable foundation Wellcome, provider of the Institutional Translation Partnership Award Fellowship; the Medical Research Council’s Impact Acceleration Account; Sight Research UK and The Underwood Trust.

References

  1. Age and gender impacts effectiveness of new gene therapy treatments for eye diseases, new study finds. News release. University of Bristol. Published 10 February, 2025. Accessed 10 February, 2025. https://bristol.ac.uk/news/2025/february-/gene-therapy-eyes-.html
  2. Clare AJ, Langer PM, Ward A, Chan YK, Dick AD, Copland DA. Characterization of the ocular inflammatory response to AAV reveals divergence by sex and age. Mol Ther. Published online January 17, 2025. doi:10.1016/j.ymthe.2025.01.028

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.